- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01162356
Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study (PROVE)
A Prospective Analysis of Nerve Fiber Layer and Macular Changes After Pars Plana Vitrectomy
Since the introduction of vitrectomy in 1971, this procedure has become the third most frequently performed ophthalmic surgery. Approximately 225,000 vitrectomies are performed annually in the United States and indications continue to expand. Known long-term complications of vitrectomy are relatively few and include retinal detachment and cataract formation. Although much has been written in the literature concerning acute rises in intraocular pressure (IOP) in the immediate postoperative period, there is surprisingly little information on long term IOP outcomes after vitrectomy. A recent report by Chang given at the LXII (62) Edward Jackson Memorial Lecture hypothesized a causal relationship between vitrectomy and open-angle glaucoma (OAG) via oxidative stress exacerbated by removal of the crystalline lens. A second report by Luk and colleagues reported similar conclusions in a modified cohort. Both studies, were retrospective in nature and did not perform baseline evaluations to exclude pre-existing glaucoma. Furthermore neither study accounted for natural history. Finally, our analysis has not reproduced similar results.
The primary purpose of this study is to analyze the full spectrum of optic nerve and macular changes between vitrectomized study eyes and their non-vitrectomized fellow eyes to control for natural history. Baseline evaluations will include examination by fellowship trained retina and glaucoma specialists, fundus photography, autofluorescence, optical coherence tomography (macula and optic nerve) and automated visual field testing. At 3 month then annually for 5 years after vitrectomy surgery, the cohort will undergo similar evaluation.
Study Overview
Status
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Vanderbilt Eye Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Able to consent and comply for the duration of the study and imaging studies
- Media clarity sufficient for imaging studies
- No previous treatment or surgery that might confound study results in the study or fellow eye
- Pars plana vitrectomy (PPV) indicated for epiretinal membrane (ERM), macular hole (MH), vitreo-macular traction (VMT), and vitreous hemorrhage (VH)
Exclusion Criteria:
- Unable to consent and/or comply for the duration of the study and imaging studies
- History of the following conditions: Glaucoma or associated conditions, visual field defects, uveitis, age-related macular degeneration (ARMD), prior PPV for retinal detachment, retained lens or dislocated intraocular lens
- Contralateral eye status post PPV or with advanced eye disease serious enough to warrant future PPV - Contralateral eye with condition that may result in choroidal neovascular membrane
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nerve fiber layer and macular changes after vitrectomy
Time Frame: 3 month and annually for 5 years after surgery
|
To determine the incidence of nerve fiber layer (NFL) and macular changes after pars plana vitrectomy, characterize their extent and quality, and determine pre-disposing risk factors.
|
3 month and annually for 5 years after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual field defects
Time Frame: 3 month and annually for 5 years after surgery
|
To characterize long-term functional consequences of NFL or macular changes with regards to peripheral and central visual field defects after PPV.
|
3 month and annually for 5 years after surgery
|
|
Open-angle glaucoma
Time Frame: 3 month and annually for 5 years after surgery
|
To determine the incidence of elevated intraocular pressure and open-angle glaucoma following vitrectomy.
Enrolled patients will be screened at baseline to exclude pre-existing glaucoma and post-operative glaucoma screenings will be performed by fellowship trained glaucoma specialist.
|
3 month and annually for 5 years after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stephen J Kim, MD, Vanderbilt Eye Institute
- Study Director: Maziar Lalezary, MD, Vanderbilt Eye Institute
- Study Director: Rahul K Reddy, MD, Vanderbilt Eye Institute
Publications and helpful links
General Publications
- Machemer R, Buettner H, Norton EW, Parel JM. Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol. 1971 Jul-Aug;75(4):813-20. No abstract available.
- Chang S. LXII Edward Jackson lecture: open angle glaucoma after vitrectomy. Am J Ophthalmol. 2006 Jun;141(6):1033-1043. doi: 10.1016/j.ajo.2006.02.014.
- Luk FO, Kwok AK, Lai TY, Lam DS. Presence of crystalline lens as a protective factor for the late development of open angle glaucoma after vitrectomy. Retina. 2009 Feb;29(2):218-24. doi: 10.1097/IAE.0b013e31818ba9ca.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 100073
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Hospices Civils de LyonRecruitingOpen-angle Glaucoma | Glaucoma Eye | Pigmentary Glaucoma | Closed-Angle Glaucoma | Pseudo Exfoliative SyndromeFrance
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Isfahan University of Medical SciencesActive, not recruitingAngle Closure Glaucoma | Glaucoma EyeIran
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
University of MiamiAbbVieRecruitingOcular Hypertension | Glaucoma | Open-Angle Glaucoma | Glaucoma SuspectUnited States
-
Ngoc Nguyen Inc.Alcon ResearchNot yet recruitingGlaucoma | Glaucoma, Open Angle | Open Angle Glaucoma (OAG) | Normal Tension Glaucoma (NTG)United States
-
Stanford UniversityNot yet recruitingPrimary Open Angle Glaucoma | Open Angle Glaucoma | Low Tension Glaucoma | Pseudoexfoliation Glaucoma | Pigmentary GlaucomaUnited States
-
Dr. Kaweh MansouriEnrolling by invitationGlaucoma, Angle-Closure | Surgery | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma; Drugs | Glaucoma, Pigmentary | Glaucoma Secondary | Glaucoma Open-Angle | Glaucoma Congenital | Glaucoma CapsulareSwitzerland